Therapeutic effect of thalidomide combined with temozolomide and three-dimensional conformal radiotherapy for patients with high-grade gliomas after operation.

PURPOSE:To explore the efficacy and safety of 125 I radioactive seed implantation combined with intermittent hormonal therapy (IHT) in the clinical treatment of moderate- and high-risk non-metastatic prostate cancer. METHODS:A total of 136 patients were divided into the observation group (n=68) and the control group (n=68). In the observation group, 125I radioactive seed implantation was performed, bicalutamide capsules were taken orally immediately after operation, and leuprorelin was injected from 1 week after operation. In the control group, IHT alone was administered. The level of serum prostate specific antigen (PSA), maximum urine flow rate (Q max ) and international prostate symptom scale (IPSS) score were compared between the two groups before and after treatment. Moreover, the overall survival (OS), tumor-specific survival (TSS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) of patients were recorded. RESULTS:There were no statistically significant differences in the PSA level, Q max and IPSS score between the two groups before treatment (p>0.05). At 6, 12 and 24 months after treatment, the level of PSA in the observation group was significantly lower than in the control group (p=0.005, p<0.001, p<0.001). At 24 months after treatment, Q max in the observation group was significantly higher than in the control group (p=0.025). At 12 and 24 months after treatment, the IPSS score in the observation group was significantly lower than that in the control group (p=0.013, p=0.002). During the follow-up period, the intermission time of hormonal therapy and PFS time in the observation group were obviously longer than those in control group (p<0.001). In the two groups, OS was 97.1% and 94.1%, TSS was 95.6% and 92.6%, DMFS was 82.4% and 66.2%, and PFS was 72.1% and 51.5%, respectively. It can be seen that OS and TSS had no statistically significant differences between the two groups (p=0.405, p=0.496), while DMFS and PFS in the observation group were remarkably superior to those in the control group (p=0.037, p=0.022). CONCLUSIONS:125 I seed implantation combined with IHT is safe and effective in the clinical treatment of patients with moderate- and high-risk non-metastatic prostate cancer. Compared with the IHT alone, the combination therapy can significantly prolong the intermission time of hormonal therapy and effectively control the progression of disease.